Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 2
Submit an article Journal homepage
414
Views
0
CrossRef citations to date
0
Altmetric
Correspondence

Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma

Barbara KiesewetterDivision of Oncology, Department of Internal Medicine I, Medical University Vienna, Vienna, Austria
&
Markus RadererDivision of Oncology, Department of Internal Medicine I, Medical University Vienna, Vienna, AustriaCorrespondence[email protected]
Pages 548-549 | Received 02 Jun 2014, Accepted 12 Jun 2014, Published online: 07 Oct 2014

References

  • Montefusco V, Galli M, Spina F, et al. Autoimmune disease during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma 2014;55:2032–2037.
  • Ekström SK, Vajdic CM, Falster M, et al. Autoimmune disorder and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029–4038.
  • Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398–405.
  • Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337–2344.
  • Wöhrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune diseases:a comparative analysis of characteristics and clinical course. Leukemia 2007;21:1812–1818.
  • Wöhrer S, Kiesewetter B, Fischbach J, et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Ann Hematol 2014;93:1287–1295.
  • Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with patients with extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Haematologica 2013;98:353–356.
  • Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;2427–2437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.